Crinetics Files Definitive Proxy for $10B Vertex Acquisition at $85/Share

summarizeSummary

Crinetics filed its definitive proxy statement for the $10 billion all-cash acquisition by Vertex at $85 per share, detailing the board's unanimous recommendation, negotiation background, fairness opinions, and a $350 million termination fee.

check_boxKey Events · M&A and Partnerships · CRNX

• Merger Agreement at $85/Share

  Vertex will acquire Crinetics for $85.00 per share in cash, a 101% premium to the unaffected price on July 2, 2026, valuing the deal at approximately $10 billion.

• Board Unanimously Recommends Approval

  The Crinetics board unanimously recommends shareholders vote FOR the merger, citing the certainty of value and the premium over recent trading prices.

• Fairness Opinions from Two Advisors

  J.P. Morgan and Leerink Partners each delivered fairness opinions, with J.P. Morgan's discounted cash flow analysis implying a per-share value range of $68.25 to $86.00, and Leerink Partners' range of $68.20 to $86.02.

• Negotiation Background Disclosed

  Vertex's initial offer was $78 per share on March 24, 2026; after multiple rounds of negotiation and due diligence, the final price of $85 was reached on July 6, 2026.

auto_awesomeAnalysis · CRNX · Life Sciences

This proxy statement provides the full blueprint for the $10 billion acquisition of Crinetics by Vertex at $85 per share in cash. It details the board's unanimous recommendation, the negotiation history that pushed Vertex's offer from $78 to $85, and the fairness opinions from J.P. Morgan and Leerink Partners. The filing also discloses a $350 million termination fee and the golden parachute compensation for executives. With the stock trading near the offer price, the key remaining catalyst is the shareholder vote, which the board strongly supports.